



OPEN ACCESS

Swallowing outcomes in dysphagia interventions in Parkinson's disease: a scoping review

Julia Hirschwald ¹, Jule Hofacker,¹ Sallyanne Duncan,² Margaret Walshe¹

10.1136/bmjebm-2022-112082

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjebm-2022-112082>).

¹Clinical Speech and Language Studies, Trinity College Dublin, Dublin, Ireland

²Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK

Correspondence to: **Julia Hirschwald**, Clinical Speech and Language Studies, Trinity College Dublin, Dublin 2, Ireland; hirschwj@tcd.ie



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Hirschwald J, Hofacker J, Duncan S, *et al.* *BMJ Evidence-Based Medicine* Epub ahead of print: [please include Day Month Year]. doi:10.1136/bmjebm-2022-112082

Abstract

Objectives To identify all outcomes, their definitions, outcome measurement instruments (OMIs), timepoints and frequency of measurement applied in clinical trials in oropharyngeal dysphagia (OD) interventions in Parkinson's disease (PD). This scoping review is the first stage of a larger project establishing a core outcome set for dysphagia interventions in Parkinson's disease (COS-DIP).

Design Scoping review.

Methods Six electronic databases and one trial registry were searched without language restrictions until March 2022. Bibliography lists of included studies were also reviewed. Study screening and data extraction were conducted independently by two reviewers using Covidence. The scoping review protocol is registered and published (<http://hdl.handle.net/2262/97652>).

Results 19 studies with 134 outcomes were included. Trial outcomes were mapped to a recommended taxonomy for COSs and merged. 39 outcomes were identified. The most frequently measured were general swallowing-related outcomes, global quality-of-life outcomes and swallowing-related perceived health status outcomes. The applied outcomes, their definitions, OMIs, timepoints and frequency of measurement showed a high variability across all studies. **Conclusions** The high variability of outcomes emphasises the need for an agreed standardised COS. This will inform clinical trial design in OD in PD, increase the quality of OD trials in PD and facilitate synthesising and comparing study results to reach conclusion on the safety and effectiveness of OD interventions in PD. It will not prevent or restrict researchers from examining other outcomes.

Trial registration number The COS-DIP study, including the scoping review, was registered prospectively with the Core Outcome Measures in Effectiveness Trials Database on 24 September 2021 (www.comet-initiative.org, registration number: 1942).

Introduction

Swallowing disorders (oropharyngeal dysphagia (OD)) are a common and clinically significant symptom in people with Parkinson's disease (PD).¹ The prevalence varies between 11% and 81% according to severity of the disease, definitions of OD and assessment tools used.² Nearly 50% of

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ There is a paucity of evidence on interventions for swallowing disorders (dysphagia) in Parkinson's disease (PD) and longer-term treatment effects and adverse events remain mostly unknown. One important reason for this is that studies examine different outcomes and use different methods of measurement making systematic reviews and meta-analyses difficult.

WHAT THIS STUDY ADDS

⇒ This scoping review identified all outcomes, their definitions, outcome measurement instruments and timepoints and frequency of measurement in clinical trials in dysphagia in PD. The results will inform the next stages of a larger project to develop a core outcome set for dysphagia interventions in Parkinson's disease (COS-DIP).

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Ultimately, the COS-DIP will provide a minimum of clearly defined outcomes that should be measured systematically and reported in all clinical trials in dysphagia in PD. This will strengthen the evidence on dysphagia interventions in PD and reduce research waste.

people with PD experience aspiration,³ increasing the risk of developing pneumonia, which is a leading cause of death in people with PD.⁴⁻⁶

OD interventions aim for safe, efficient and sufficient intake of food and fluids for patients while maximising quality of life (QoL) for the patient, their carers and their family.⁴ Clinical decisions on the safety and effectiveness of interventions are based on selected outcomes, thus the choice of outcomes to be measured and reported in clinical trials is critical.⁷

Furthermore, synthesising and comparing study results to direct treatment for people with OD in PD is necessary. Two recently published systematic reviews by Gandhi and Steele⁸ and López-Liria *et al*⁹ concluded that there is an ongoing significant

lack of fundamental scientific evidence on the treatment of OD in PD. In an attempt to address this issue, Schindler *et al*¹⁰ established a consensus on the treatment of OD in PD. One conclusion made by the authors is that in neurodegenerative conditions such as PD, longer-term treatment effects and adverse events must also be assessed.

These three published reports demonstrate not only a deficiency of evidence on OD interventions in PD but argue that longer-term treatment effects and adverse events should be assessed consistently. Despite being intricately linked, these studies focus on the efficacy and efficiency of OD interventions themselves rather than on the outcomes that are targeted by the interventions.

Core outcome set for dysphagia interventions in Parkinson's disease (COS-DIP)

A solution to these challenges is the development and use of an agreed standardised COS-DIP devised by key stakeholders including patients, healthcare professionals and clinical trialists. This will result in higher quality meaningful trials, which will enhance synthesising and comparing individual study results to reach conclusions on the safety and effectiveness of the interventions. It will not prevent or restrict researchers from examining other outcomes.^{7 11}

In order to establish the COS-DIP, the first step is a scoping review of the literature on the applied outcomes in clinical trials in OD in PD. A scoping review was chosen as the most appropriate method to systematically map the research done in this area, as well as to identify any existing gaps in knowledge.¹²

The objective of this scoping review was to report on all applied outcomes, their definitions, outcome measurement instruments (OMIs) and timepoints and frequency of measurement in (quasi-) randomised controlled trials (RCTs), controlled clinical trials (CCTs) and pilot/feasibility studies with control groups in OD in PD. This extracted information is brought together in a 'long list of outcomes' and will be used to inform the development of the COS-DIP. The following research questions were sought to be answered:

1. What are the outcomes of interest in clinical trials in OD in PD?
2. How are the outcomes in these clinical trials defined?
3. How are the outcomes in these clinical trials measured?
4. At which timepoints and at which frequency are the outcomes in these clinical trials measured?

Patient and public involvement

We did not involve patients or members of the public in the design or conduct of this scoping review. For all following stages of the COS-DIP we have established a study steering committee that will lead and conduct the development of the COS-DIP and includes a public research partner with PD.

Methods

Study protocol and registration

This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis extension for Scoping Reviews (PRISMA-ScR) checklist (see online supplemental file 1).¹³ A review protocol was devised beforehand and published online (<http://hdl.handle.net/2262/97652>). The COS-DIP study, including the scoping review, was registered prospectively with the Core Outcome Measures in Effectiveness Trials (COMET) Database on 24 September 2021 and

was last revised on 20 December 2021 (www.comet-initiative.org, registration number: 1942).

Searches

A comprehensive search strategy, including two search strings (1) dysphagia and (2) Parkinson's Disease, was devised with the assistance of a subject librarian. The databases AMED, CINAHL, EMBASE, MEDLINE, Web of Science, ProQuest Dissertations & Theses and trial registry Clinicaltrials.gov were searched from inception to 3 December 2021 and updated on 10 March 2022 (see online supplemental file 2). The reference lists of all included studies were screened for additional studies and study authors were contacted for additional information, if required.

Study inclusion and exclusion criteria

Studies were included if (1) participants had a diagnosis of OD and PD, (2) clinical interventions were aimed at improving swallowing or feeding difficulties, (3) at least one swallowing (related) outcome was measured and (4) the study design included at least one intervention and one control group (RCT, quasi-RCT, CCT or feasibility/pilot study with control group). Only studies with control groups were included as ultimately the COS-DIP will inform clinical trial design with a focus on RCTs so that meta-analysis of clinical trials in OD and PD will be feasible in the future. In accordance with the patient, concept and context framework,¹³ the following was applied:

- ▶ Patient: OD in idiopathic PD ≥ 18 years.
- ▶ Concept: any clinical intervention in OD in PD.
- ▶ Context: any clinical context (all countries and healthcare settings, eg, acute care, primary healthcare and community setting).

Studies were excluded if they did not fit into the conceptual framework of the study or if a heterogeneous participant population including people with PD was studied but data could not be extracted for the PD subgroup solely. Finally, studies were excluded if no full text was available, eg, a conference abstract only, and authors were unable to provide sufficient information. No date or language restrictions were applied.

Study selection

Following the search, all identified citations were collated and uploaded to an online platform (www.covidence.org), where duplicates were removed automatically. A pilot test of a random sample of 25 titles and abstracts was carried out by 2 independent reviewers (JHirschwald and JHofacker) and achieved an agreement of 96% (preset cut-off was set at 75%). Following, all abstracts and titles and thereafter full texts, were screened independently by JHirschwald and JHofacker against the inclusion criteria. Any disagreement that arose between the reviewers at each stage of the selection process was either resolved through discussion or with an additional reviewer (MWalshe).

Data extraction strategy

Data was extracted independently from papers included in the scoping review by JHirschwald and JHofacker using a data extraction tool developed previously and applied by Hofacker.¹⁴ The extracted data includes details about the first author's name, year of publication, country of origin, study design, population, sample size and applied outcomes. The data extraction form was trialled independently on three included sources by JHirschwald and JHofacker. As a result of discussion together with MWalshe, further parameters were added to the data extraction form: number of participants and dropouts, intention-to-treat analysis, age,

gender, PD severity, OD severity, intervention, comparator, OMI, timepoints of measurement and frequency of measurement (see online supplemental file 3). Any disagreements that arose were resolved through discussion between JHirschwald and JHofacker, or with MWalshe in addition.

Data analysis and presentation

As no taxonomy for categorisation of outcomes in OD interventions specifically exists, a widely used taxonomy by Dodd *et al*¹⁵ was applied. This taxonomy was designed for trial outcomes and is applicable to all fields within medical research.^{7 16} It includes 5 core areas (death, physiological/clinical, life impact, resource use and adverse events) and 38 outcome domains.¹⁵

The outcomes used in the included studies were extracted as verbatim following COS methodology as described in the COMET Handbook.⁷ All extracted data were categorised in an Excel spreadsheet also previously developed and applied by Hofacker¹⁴ and further adapted for the purpose of this study. It comprises information regarding core area of the outcome and outcome domain in accordance with the taxonomy by Dodd *et al*,¹⁵ outcome description as reported verbatim by study authors, definition of outcome, OMI and timepoints and frequency of measurement. Furthermore, the amount and percentages of used outcomes within the respective core area and outcome domain were calculated.

Results

Search results

The literature search identified 2587 studies. After removal of duplicates, further 2328 records were excluded during title/abstract screening. Of the remaining 54 reports, 9 could not be retrieved as full texts and 27 did not meet the inclusion criteria in the full-text review (see online supplemental file 8). Additionally, two records were identified through citation searching, of

which one was included. In total, 19 studies were included in this scoping review. Of these, 18 were in English and one in Chinese. The Chinese study was translated with the help of a translator and Chinese speaking Speech and Language Therapist. The results of the search and the study inclusion process are outlined in the PRISMA-ScR flow diagram in figure 1.^{13 17}

The included studies comprised 10 RCTs, 2 quasi-RCTs, 4 CCTs and 3 feasibility/pilot studies with control groups. Overall, 2124 participants were included with studies being published between the years 2000 and 2021, although all years were included in the search. Assessed interventions in the included studies were surface electrical stimulation (n=4), postural swallowing techniques (n=3), Expiratory Muscle Strength Training (n=3), application of biofeedback (n=2), repetitive transcranial magnetic stimulation (rTMS) (n=2), standardised swallowing training (n=2), deep brain stimulation (n=1), vocal training (n=1) and aural stimulation with capsaicin (n=1) (see online supplemental file 3 for the detailed characteristics of the included studies).

Within the 19 studies, 180 outcomes were identified. Of these, 46 outcomes were excluded for different reasons: (1) the outcomes were only assessed for determining whether the participants met the inclusion criteria for study participation but not the effect of the intervention, (2) neither the specific OMI nor results were reported or (3) due to missing information it was unclear what the outcome referred to (see online supplemental file 4).

Outcome areas

The majority of the 134 included outcomes belong to the outcome areas physiological/clinical (n=112; 83.58%) or life impact/functioning (n=19; 14.18%). One outcome was categorised to each of the outcome areas death, resource use and adverse events (n=1; 0.75% respectively).




Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-analysis extension for Scoping Reviews flow diagram.




Figure 2 Outcome domains used in clinical trials in oropharyngeal dysphagia in Parkinson's disease.

Outcome domains

As the taxonomy by Dodd *et al*¹⁵ was developed for clinical trials in medical research in general but not specifically for OD interventions, the outcome domains were adapted for the purpose of this scoping review. Figure 2 depicts the outcome domains from the included studies and the number of outcomes mapped accordingly.

Outcome subdomains

The outcome domain #9a comprises almost three quarters of all outcomes and the outcome domain #9b includes with over 8% the second most outcomes. In order to categorise these general outcome domains more precisely, recategorising according to subdomains was necessary. Outcome domain #9a was divided into the following five subdomains: (1) saliva management, (2) swallowing-related physiology, (3) swallow efficiency, (4) swallow safety and (5) neurological status. The outcome oropharyngeal dysphagia severity remained as was. Outcome domain #9b was split into two subdomains: (1) neurological findings and (2) voice.

Research question 1: what are the outcomes of interest in clinical trials in OD in PD?

The 134 included outcomes were merged to 39 outcomes due to overlaps or being identical. Table 1 presents the 'long list of outcomes' including the outcomes, subdomains, domains and outcome areas accordingly.

The outcome of most interest was penetration/aspiration measuring the depth of the entry of food and fluid into the larynx and airway. This was measured in 10 of the 19 studies. Oropharyngeal dysphagia severity was the second most often measured outcome (n=9). The top eight outcomes of interest in the included studies are depicted in figure 3. All other outcomes were measured one or two times.

Of these top eight outcomes, six belong to the outcome domain #9a general swallowing-related outcomes, whereas the other two belong to the outcome domain #30 global quality of life and #31a swallowing-related perceived health status.

Research question 2: how are the outcomes in these clinical trials defined?

Most definitions of the outcomes in the included studies vary widely. Thereof, 17 outcomes were not defined at all in any study,

and 13 outcomes were defined by some studies but not by others. The outcomes swallowing-related hyoid bone movement and timing of oropharyngeal swallowing components were the most diverse defined outcomes. Each study used different parameters within these outcomes with either very specific or no definition. Outcomes that were assessed by using a scale or questionnaire were oftentimes not defined at all. Instead, the numerical scores from the scale or questionnaire were provided without explanation of what they related to. The outcome penetration/aspiration was defined in accordance with the definition by Rosenbek *et al* in 9 of 10 studies: 'Penetration is defined [...] as passage of material into the larynx that does not pass below the vocal folds. Aspiration is defined as passage of material below the level of the vocal folds.'¹⁸ There was no matching definition for any other outcome by at least two studies with different authors. The definitions of outcomes reported by Bajjens *et al*^{19 20} were unsurprisingly in agreement given that both studies were conducted by the same main author group (see online supplemental file 5 for all definitions of outcomes).


Research question 3: how are the outcomes in these clinical trials measured?

Overall, the applied OMIs show high variability. Most of the outcomes in the outcome domain #9a were measured using instrumental assessments and either validated scales or scales designed for the purpose of the according study during videofluoroscopic evaluation of swallowing (VFS) (also referred to Modified Barium Swallow Study) or Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or measuring it in milliseconds during electromyography.

The outcomes penetration/aspiration and swallowing-related quality of life were measured the most consistently. Eight of the ten studies used the Penetration-Aspiration-Scale (PAS) by Rosenbek *et al*¹⁸ during VFS and/or FEES. One study²¹ did not report the scale that was used to measure the outcome during VFS and another study²² used a self-designed 4-point scale. The outcome swallowing-related quality of life was measured through the Swallowing Quality of Life (SWAL-QOL)²³ Questionnaire in six studies, whereas one study²⁴ additionally assessed this outcome through the MD Anderson Dysphagia Inventory.²⁵ The outcome self-perception of swallowing was measured by the Swallowing Disturbance Questionnaire²⁶ three times and the Dysphagia

Table 1 Long list of outcomes included in clinical trials in oropharyngeal dysphagia in Parkinson's disease

Outcome area	Outcome domain	Outcome subdomain	Outcome
Death	1. Mortality/survival		Death
Physiological/ clinical	9a. General swallowing-related outcomes	Saliva management	Oropharyngeal dysphagia severity
			Drooling
		Swallowing-related physiology	Salivary pooling
			Orolingual bolus control
			Oral bolus transport
			Swallowing-related lingual movement
			Timing of oropharyngeal swallow components
			Laryngeal elevation
		Swallow efficiency	Laryngeal sensation
			Swallowing-related hyoid bone movement
	Initiation of pharyngeal swallow		
	Postswallow oral residue		
	Swallow safety	Postswallow pharyngeal residue	
		Postswallow pharyngeal pooling	
	Neurological status	Piecemeal deglutition	
		Penetration/aspiration	
	9b. General non-swallowing-related outcomes	Neurological findings	Cortical reorganisation
			Motor evoked potential
			Overall motor symptoms
			Tremor
Rigidity			
Bradykinesia			
Voice		Axial symptoms	
		Freezing of gait	
		Phonation	
		Loudness	
14. Nutritional and dietary outcomes	Level of oral intake		
22. Respiratory outcomes	Aspiration pneumonia		
Life impact/ functioning	25. Non-swallowing-related physical functioning	Activities of daily living	
	28. Emotional functioning/well-being	Pleasure of oral intake	
	30. Global quality of life	Swallowing-related quality of life	
	31a. Swallowing-related perceived health status	Self-perception of swallowing	
	31b. Non-swallowing-related perceived health status	Self-perception of walking	
	32. Delivery of care	Self-perception of activities of daily living	
Resource use	35. Hospital	Participant's satisfaction with intervention	
Adverse events	38. Adverse events/effects	Participant's adherence to intervention	
		Hospitalisation	
		Adverse events	

**Figure 3** Number of studies measuring each outcome in clinical trials in oropharyngeal dysphagia in Parkinson's disease.

Severity Scale (DSS)²⁷ and Arabic Dysphagia Handicap Index²⁸ once each.

The outcome oropharyngeal dysphagia severity was the outcome measured most differently across all included studies. In order to assess the outcome either validated scales or self-designed scales for VFS and/or FEES, the Standardized Swallow Assessment²⁹ or a Clinical Swallow Evaluation were conducted. The OMI of death and hospitalisation were not described and while it may seem self-explanatory, their methods of recording were not clear (see online supplemental file 6 for the applied OMIs).

Research question 4: at which timepoints and at which frequency are the outcomes in these clinical trials measured?

In the outcome domains #1, #22, #35 and #38 only one study³⁰ assessed the outcomes death, aspiration pneumonia, hospitalisation and adverse events, respectively. These were measured

continuously over a period of 3 months without further details provided by the authors. All remaining outcomes in the outcome area physiological/clinical were measured in the included studies one to five times either during or pre to post and/or with one to two follow-ups. The timepoints post intervention ranged from 5 min to 6 months.

The outcomes in the outcome area life impact/functioning were measured 1–36 times during, pre and/or post with follow-up assessments 2 weeks to 6 months post intervention. The outcome participant's adherence to intervention was assessed weekly over a period of 3 months, hence 36 times in 1 study.³⁰ The outcome self-perception of swallowing was measured differently at varying timepoints and frequency across the included studies. For example, 1 study²⁴ assessed the outcome through the DSS²⁷ after each session, hence 13–15 times, whereas the other 4 studies^{22 31–33} assessed it 2, 3 or 5 times. Only the outcome participant's satisfaction with the intervention was measured once during or 2 weeks post intervention.

Overall, most outcomes were measured at least pre and post intervention with frequencies from one to four times. If the outcome was measured only once this was usually during the intervention, for example, rTMS (see online supplemental file 7 for all timepoints and frequency of measurements).

Discussion

In this scoping review, 19 clinical trials that investigated OD interventions in PD with 134 outcomes were included. Outcomes were merged to 39 final outcomes in 13 outcome domains. Outcomes of interest, definitions, OMI, timepoints and frequency of measurement varied highly across the included studies. This scoping review identified relevant challenges within the included studies.

One major challenge in the included studies is the lack of information on outcomes, their definitions, and OMI and omitted outcomes. For example, three studies did not report on outcomes in detail if there were no differences between the intervention and the control group.^{19 20 34} In two other studies, the authors did not report why outcomes were omitted.^{24 35} Incomplete reporting of research methods (eg, what was measured and how was it measured) and selective reporting of findings (eg, omitted outcomes) decrease the transparency of the research studies and raise questions about the applicability of the findings and study reporting practices. This heightens the risk that results lack credibility and studies are not easy to replicate and reproduce.^{36–38} This is especially problematic in healthcare research involving OD interventions in PD where the outcomes of these clinical trials are essential for decision-making, such as the safety and effectiveness of the intervention.⁷

Another identified challenge in the included studies is that some of the outcomes that were previously identified in the literature as relevant for people with OD and PD were not or rarely assessed. Only one study³⁹ included the outcome voice as they assessed the effect of vocalisation training in improving drooling in people with PD. However, three pilot studies have previously shown that cross system effects through an intensive, evidence-based voice and speech treatment (Lee Silverman Voice Treatment, LSVT LOUD) in people with PD can improve swallowing.^{40–42} These studies suggest that training voice and speech may improve swallow function as well. Concurrently, dysphagia therapy might affect voice and speech in PD. Therefore, voice as an outcome in clinical trials in OD in PD might be relevant to assess.

Just 6 of the 19 included studies assessed swallowing-related quality of life and five studies included self-perception of swallowing as patient-reported outcomes. This is a relatively small

number, as patient-reported outcomes are considered critical for evidence-based practice and for assessing treatment effectiveness.⁴³ It should be noted that specifically in people with PD the self-assessment may differ from objective or investigator-reported outcomes due to sensorimotor deficits^{44 45} and hence, both types of assessments should be included.

Outcomes that were not typically measured but may be considered relevant included parameters associated with cough, hydration and nutrition. People with OD in PD are at high risk of developing malnutrition and dehydration. This can further impair swallow function and delay the rehabilitation process. It can also increase the risk of medical complications or even mortality.⁴⁶ Furthermore, impaired cough (dystussia) reduces airway protection as material entering the airway might not be expelled effectively. Dystussia often coexists with OD in people with PD and therefore the risk of aspiration and pneumonia is increased, but also QoL can be decreased.^{47 48} This is not surprising as both coughing and swallowing are sensorimotor behaviours that overlap in anatomy and neuroanatomical substrates.⁴⁷ Therefore, outcomes associated with hydration, nutrition and cough might be relevant to assess in future OD interventions in PD.

A further interesting finding in this review is that only one study³⁰ assessed outcomes pertaining to the outcome areas of death, resource use and adverse events. Assessing and reporting adverse events in RCTs is crucial for determining the safety of an intervention, but is less focused on than assessing and reporting efficacy and effectiveness in these trials.⁴⁹ The outcome area adverse events might comprise numerous outcomes, which typically are not predefined as they are usually unknown before commencing a study. Furthermore, only assessing if adverse events are present or absent is regarded as insufficient. Additional information on the severity, timing, duration and number of occurrences of the events is required and thus, making the assessment, reporting and analysis of these outcomes more laborious and possibly inconsistent.⁵⁰ Death might be incorporated as an outcome of adverse events. In OD interventions in PD, the assessment and reporting of death might be more relevant than currently considered. As stated before, dysphagia and dystussia increase the risk of aspiration and hence pneumonia, which is a leading cause of death in people with PD. Therefore, addressing this outcome area in future clinical trials in addition with adverse events might be relevant. The reporting of adverse events in clinical trials might further be improved by the adoption of the Consolidated Standards of Reporting Trials harm extension guideline.⁴⁹

Following the Dodd *et al*¹⁵ taxonomy, the outcome area resource use comprises the outcome domains economic, hospital, need for further intervention and societal/carer burden. Of these, only hospital in terms of length of hospital stay was assessed in one of the included studies. This outcome area might be under-represented in OD in PD studies. A recent systematic review showed that the presence of dysphagia increases the hospital length of stay, regardless of admission cause. Furthermore, this also increases the monetary costs by over 40% in patients with dysphagia compared with non-dysphagic patients. In addition, pneumonia is one of the most common reasons for emergency hospital admission in patients with PD,⁵¹ making patients with OD in PD more likely to be admitted to hospital and increase overall healthcare costs. Additionally, Perry *et al*⁵² found that providing care for a person with OD in PD reduces the carer's QoL due to an increased burden. In future studies on OD in PD, it might be important to assess outcomes related to carer burden as ultimately, a less burdened carer might improve a PD person's health outcomes and QoL.⁵²

Lastly, the use of unvalidated OMI (in general or for the specific patient population) in the included studies comprised a further challenge.^{24 53} Validated OMIs are important to ensure that the tool is measuring what it is supposed to measure, and hence, that the results are valid.

Strengths and limitations of the study

In order to categorise the outcomes, the taxonomy devised by Dodd *et al*¹⁵ was applied as recommended by the COMET Handbook. This is widely implemented in outcome research and facilitates consistent use of clinical outcome terms.^{7 15} However, the taxonomy was devised largely for medical research, making it less specific to OD interventions. Furthermore, a possible limitation in this review is the restriction of the review to include clinical trials only, but this was based on the fact that the focus of the COS-DIP is a COS for clinical trial design.

Conclusion

This is the first scoping review that has systematically extracted and categorised all outcomes in clinical trials in OD interventions in PD. We identified high variability in included outcomes in addition to outcomes that were rarely measured or not measured at all. Furthermore, a lack of information on outcomes, such as definitions, OMIs and timepoints of measurement, was identified which can affect a study's replicability, credibility and decrease its validity. Additionally, in some of the included studies, outcomes mentioned as part of the study's research question were later omitted and hence pose a risk of reporting bias and skewing individual study results.

Through the development of the COS-DIP, the minimum core outcomes to be measured and reported in all future OD interventions in PD will be agreed on and advice on how and when to measure these will be provided. Ultimately, this will increase the quality of OD trials in PD and reduce research waste. It will not prevent or restrict researchers from examining other outcomes.

Deviation from protocol

In addition to (quasi-) RCTs and CCTs also, feasibility/pilot studies with control groups were included in this scoping review. This allows for inclusion of all clinical trial designs. No other deviations were made from the study protocol.

Acknowledgements We acknowledge the work of Ms Isolde Harpur, Subject Librarian of Clinical Speech and Language Studies, Trinity College Dublin, Ireland.

Contributors JHirschwald drafted the manuscript. JHofacker was second reviewer. Discussions on inclusion/exclusion of studies were discussed and solved with MWalshe. The long list of outcomes was agreed on by all authors. All authors critically appraised and edited the manuscript. All authors read and approved the final manuscript. MWalshe is the guarantor for this study.

Funding The first author JHirschwald undertakes this research project as part of a Provost's PhD Award funded by Trinity College Dublin, Ireland.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information. All data generated or analysed during this study are included in this published article and its online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Julia Hirschwald <http://orcid.org/0000-0001-6707-6921>

References

- 1 Suttrup I, Warnecke T. Dysphagia in Parkinson's disease. *Dysphagia* 2016;31:24–32.
- 2 Takizawa C, Gemmell E, Kenworthy J, *et al*. A systematic review of the prevalence of oropharyngeal dysphagia in stroke, Parkinson's disease, Alzheimer's disease, head injury, and pneumonia. *Dysphagia* 2016;31:434–41.
- 3 Warnecke T, Suttrup I, Schröder JB, *et al*. Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test. *Parkinsonism Relat Disord* 2016;28:100–6.
- 4 Crary MA, Groher ME. *Dysphagia: clinical management in adults and children*. Elsevier Health Sciences, 2016.
- 5 Hobson P, Meara J. Mortality and quality of death certification in a cohort of patients with Parkinson's disease and matched controls in North Wales, UK at 18 years: a community-based cohort study. *BMJ Open* 2018;8:e018969.
- 6 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* 1967;17:427–42.
- 7 Williamson PR, Altman DG, Bagley H, *et al*. The comet Handbook: version 1.0. *Trials* 2017;18:280.
- 8 Gandhi P, Steele CM. Effectiveness of interventions for dysphagia in Parkinson disease: a systematic review. *Am J Speech Lang Pathol* 2022;31:463–85.
- 9 López-Liria R, Parra-Egeda J, Vega-Ramírez FA, *et al*. Treatment of Dysphagia in Parkinson's Disease: A Systematic Review. *Int J Environ Res Public Health* 2020;17:4104.
- 10 Schindler A, Pizzorni N, Cereda E, *et al*. Consensus on the treatment of dysphagia in Parkinson's disease. *J Neurol Sci* 2021;430:120008.
- 11 Gargon E, Williamson PR, Altman DG, *et al*. The comet initiative database: progress and activities from 2011 to 2013. *Trials* 2014;15:279.
- 12 Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8:19–32.

- 13 Tricco AC, Lillie E, Zarin W, *et al*. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169:467–73.
- 14 Hofacker J. *Developing a core outcome set in oral stimulation interventions for preterm infants – Step 1: A scoping review of current trial outcomes [unpublished master thesis]*. Dublin: Trinity College Dublin, 2021.
- 15 Dodd S, Clarke M, Becker L, *et al*. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *J Clin Epidemiol* 2018;96:84–92.
- 16 Katiri R, Hall DA, Killan CG, *et al*. Systematic review of outcome domains and instruments used in designs of clinical trials for interventions that seek to restore bilateral and binaural hearing in adults with unilateral severe to profound sensorineural hearing loss ('single-sided deafness'). *Trials* 2021;22:220.
- 17 Page MJ, McKenzie JE, Bossuyt PM, *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
- 18 Rosenbek JC, Robbins JA, Roecker EB, *et al*. A penetration-aspiration scale. *Dysphagia* 1996;11:93–8.
- 19 Baijens LWJ, Speyer R, Passos VL, *et al*. The effect of surface electrical stimulation on swallowing in dysphagic Parkinson patients. *Dysphagia* 2012;27:528–37.
- 20 Baijens LWJ, Speyer R, Passos VL, *et al*. Surface electrical stimulation in dysphagic Parkinson patients: a randomized clinical trial. *Laryngoscope* 2013;123:E38–44.
- 21 Logemann JA, Gensler G, Robbins J, *et al*. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. *J Speech Lang Hear Res* 2008;51:173.
- 22 Manor Y, Mootanah R, Freud D, *et al*. Video-Assisted swallowing therapy for patients with Parkinson's disease. *Parkinsonism Relat Disord* 2013;19:207–11.
- 23 McHorney CA, Robbins J, Lomax K, *et al*. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. documentation of reliability and validity. *Dysphagia* 2002;17:97–114.
- 24 Heijnen BJ, Speyer R, Baijens LWJ, *et al*. Neuromuscular electrical stimulation versus traditional therapy in patients with Parkinson's disease and oropharyngeal dysphagia: effects on quality of life. *Dysphagia* 2012;27:336–45.
- 25 Chen AY, Frankowski R, Bishop-Leone J, *et al*. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. *Arch Otolaryngol Head Neck Surg* 2001;127:870–6.
- 26 Manor Y, Giladi N, Cohen A, *et al*. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. *Mov Disord* 2007;22:1917–21.
- 27 Tohara H, Palmer JB, Reynolds K, *et al*. [Dysphagia severity scale]. *Kokubyo Gakkai Zasshi* 2003;70:242–8.
- 28 Farahat M, Malki KH, Mesallam TA, *et al*. Development of the Arabic version of dysphagia handicap index (DHI). *Dysphagia* 2014;29:459–67.
- 29 Perry L. Screening swallowing function of patients with acute stroke. Part two: detailed evaluation of the tool used by nurses. *J Clin Nurs* 2001;10:474–81.
- 30 Robbins J, Gensler G, Hind J, *et al*. Comparison of 2 interventions for liquid aspiration on pneumonia incidence: a randomized trial. *Ann Intern Med* 2008;148:509.
- 31 Claus I, Muhle P, Suttrup J, *et al*. Expiratory muscle strength training (EMST) for treatment of pharyngeal dysphagia in Parkinson's disease: A randomized controlled trial. *Dysphagia* 2020;35:143.
- 32 Khedr EM, Mohamed KO, Soliman RK, *et al*. The effect of high-frequency repetitive transcranial magnetic stimulation on advancing Parkinson's disease with dysphagia: double blind randomized clinical trial. *Neurorehabil Neural Repair* 2019;33:442–52.
- 33 Xie T, Bloom L, Padmanaban M, *et al*. Long-Term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. *J Neurol Neurosurg Psychiatry* 2018;89:989–94.
- 34 Ayres A, Jotz GP, Rieder CRM, *et al*. Benefit from the Chin-Down maneuver in the swallowing performance and Self-Perception of Parkinson's disease patients. *Parkinsons Dis* 2017;2017:7460343.
- 35 da Silva MMA, Brasolotto AG, de LGR, *et al*. Can adjunctive electromyographic biofeedback help maintain long-term prophylactic swallowing therapy results in Parkinson's disease? A pilot study. *Audiol Commun Res* 2021;26:e2542.
- 36 John LK, Loewenstein G, Prelec D. Measuring the prevalence of questionable research practices with incentives for truth telling. *Psychol Sci* 2012;23:524–32.
- 37 Samsa G, Samsa L. A guide to reproducibility in preclinical research. *Acad Med* 2019;94:47–52.
- 38 El Amin M, Borders JC, Long H. Open Science Practices in Communication Sciences and Disorders: A Survey [Internet]. *Open Science Framework* 2022 <https://osf.io/jwba3>
- 39 Feng QL, Cheng YY, Liu PP, *et al*. Effects of vocalization training on drooling severity in Parkinson's disease. *Chin J Contemp Neurol Neurosurg* 2019;19:891–6.
- 40 El Sharkawi A, Ramig L, Logemann JA, *et al*. Swallowing and voice effects of Lee Silverman voice treatment (LSVT): a pilot study. *J Neurol Neurosurg Psychiatry* 2002;72:31–6.
- 41 Miles A, Jardine M, Johnston F, *et al*. Effect of Lee Silverman voice treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: a pilot study. *J Neurol Sci* 2017;383:180–7.
- 42 Park A, Jang S-J, Kim N-E, *et al*. Swallowing outcomes following voice therapy in multiple system atrophy with dysphagia: comparison of treatment efficacy with Parkinson's disease. *Dysphagia* 2022;37:198–206.
- 43 Watts CR, Zhang Y. Progression of self-perceived speech and swallowing impairment in early stage Parkinson's disease: longitudinal analysis of the unified Parkinson's disease rating scale. *J Speech Lang Hear Res* 2022;65:146–58.
- 44 Kalf JG, de Swart BJM, Bloem BR, *et al*. Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis. *Parkinsonism Relat Disord* 2012;18:311–5.
- 45 Pflug C, Bihler M, Emich K, *et al*. Critical dysphagia is common in Parkinson disease and occurs even in early stages: a prospective cohort study. *Dysphagia* 2018;33:41–50.
- 46 Wirth R, Dzewas R, Beck AM, *et al*. Oropharyngeal dysphagia in older persons - from pathophysiology to adequate intervention: a review and summary of an international expert meeting. *Clin Interv Aging* 2016;11:189–208.
- 47 Troche MS, Brandimore AE, Godoy J, *et al*. A framework for understanding shared substrates of airway protection. *J Appl Oral Sci* 2014;22:251–60.
- 48 Troche MS, Schumann B, Brandimore AE, *et al*. Reflex cough and disease duration as predictors of swallowing dysfunction in Parkinson's disease. *Dysphagia* 2016;31:757–64.
- 49 Ioannidis JPA, Evans SJW, Gøtzsche PC, *et al*. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004;141:781.
- 50 Phillips R, Hazell L, Sauzet O, *et al*. Analysis and reporting of adverse events in randomised controlled trials: a review. *BMJ Open* 2019;9:e024537.
- 51 Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. *Mov Disord* 2005;20:1104–8.
- 52 Perry SE, Borders JC, Dakin AE, *et al*. Characterizing quality of life in caregivers of people with Parkinson's disease and dysphagia. *Dysphagia* 2022;37:523–32.
- 53 Byeon H. Effect of simultaneous application of postural techniques and expiratory muscle strength training on the enhancement of the swallowing function of patients with dysphagia caused by Parkinson's disease. *J Phys Ther Sci* 2016;28:1840–3.

Additional file 1: PRIMSA-ScR Checklist

Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	1-2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3-5
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	5
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	6-7
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	6
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Additional file 2
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	7
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	8
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	Not applicable

Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	8-9
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	9
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	9
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	10-16
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	10-16
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	16-18
Limitations	20	Discuss the limitations of the scoping review process.	18
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	19
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	21

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850).

Additional file 2: Search Strategy

Search strategy		
AMED		
#	Search strategy	Results
S3	S1 AND S2	2
S2	SU parkinson disease OR TI (idiopathic parkinson's disease OR idiopathic parkinsons disease OR idiopathic parkinsons' disease OR idiopathic parkinson disease) OR AB (idiopathic parkinson's disease OR idiopathic parkinsons disease OR idiopathic parkinsons' disease OR idiopathic parkinson disease)	80
S1	SU dysphagia OR TI (dysphagi* OR deglutition OR swallow*) OR AB (dysphagi* OR deglutition OR swallow*)	1.019
CINAHL		
S8	S5 AND S6 (Limiters - Exclude MEDLINE records)	149
S7	S5 AND S6	388
S6	S3 OR S4	24.108
S5	S1 OR S2	20
S4	T1 (idiopathic parkinson's disease OR idiopathic parkinsons disease OR idiopathic parkinsons' disease OR idiopathic parkinson disease) OR AB (idiopathic parkinson's disease OR idiopathic parkinsons disease OR idiopathic parkinsons' disease OR idiopathic parkinson disease)	860
S3	(MH "Parkinson Disease")	
S2	TI (dysphagi* OR deglutition OR swallow*) OR AB (dysphagi* OR deglutition OR swallow*)	17.089
S1	(MH "Deglutition Disorders")	
EMBASE		
	8 #7 AND (embase/lim NOT ((embase/lim AND [medline]/lim)	1.560
	7 #3 AND #6	2.796
	6 #4 OR #5	174.509
	5 idiopathic parkinson/s disease:ab,ti OR idiopathic parkinsons disease:ab,ti OR idiopathic parkinsons/ disease:ab,ti OR "idiopathic parkinson disease":ab,ti	4.939
	4 parkinson disease/exp	174.081
	3 #1 OR #2	126.373
	2 dysphagi*:ab,ti OR deglutiti:ab,ti OR swallow*:ab,ti	92.668
	1 'dysphagia"/exp	85.162
ProQuest		
	notf(dysphagi* OR deglutition OR swallow*) AND notf(idiopathic parkinson's disease OR idiopathic parkinson disease OR idiopathic parkinson' disease OR idiopathic parkinson disease)	6
PubMed		
#7	((("Parkinson Disease" [Mesh]) OR (idiopathic parkinson's disease[Title/Abstract] OR idiopathic parkinsons disease[Title/Abstract] OR idiopathic parkinsons' disease[Title/Abstract] OR idiopathic parkinson disease[Title/Abstract])) AND (("Deglutition Disorders"[Mesh]) OR (dysphagi*[Title/Abstract] OR deglutition[Title/Abstract] OR swallow*[Title/Abstract])))	763
#6	("Parkinson Disease" [Mesh]) OR (idiopathic parkinson's disease[Title/Abstract] OR idiopathic parkinsons disease[Title/Abstract] OR idiopathic parkinsons' disease[Title/Abstract] OR idiopathic parkinson disease[Title/Abstract])	74.422
#5	idiopathic parkinson's disease[Title/Abstract] OR idiopathic parkinsons disease[Title/Abstract] OR idiopathic parkinsons' disease[Title/Abstract] OR idiopathic parkinson disease[Title/Abstract]	336
#4	Parkinson Disease [Mesh]	73.538
#3	("Deglutition Disorders" [Mesh]) OR (dysphagi*[Title/Abstract] OR deglutition[Title/Abstract] OR swallow*[Title/Abstract])	94.511
#2	dysphagi*[Title/Abstract] OR deglutition[Title/Abstract] OR swallow*[Title/Abstract]	58.181
#1	Deglutition Disorders[Mesh]	55.955
Web of Science		
	3 (#1) AND #2	106
	2 TS=(idiopathic parkinson's disease OR idiopathic parkinsons disease OR idiopathic parkinsons' disease OR idiopathic parkinson disease)	7.220
	1 dysphagi* OR deglutition OR swallow* (Topic)	60.163
Clinicaltrials.gov		
	dysphagia Interventional Studies Parkinson Disease	24

Additional file 3: Data extraction chart

Complete data extraction

1st author's name, year	Country	Study design	N (dropouts)	Intention to treat analysis	Age	Gender	PD severity	OD severity	Intervention	Comparator	Applied outcome measures + way of measurement	Timepoints	Frequency
Ayres, 2017	Brazil	CCT	32 (8)	No	IG: 62.0 (SD±11.5) CG1: 62.8 (SD±6.2) CG2: 64.5 (SD±5.6)	m=18, f=6	IG: 2.8 (SD±0.8) CG1: 2.5 (SD±0.7) CG2: 2.5 (SD±0.8)	FOIS: IG: 5.9 (SD ±1.3) CG1: 6.8 (SD±0.5) CG2: 6.8 (SD±0.4)	Chin-down posture maneuver	CG1: no intervention CG2: swallowing orientations	> FEES: - prior state of secretion in nasopharyngeal structures, oropharynx, laryngopharynx - presence/absence of: thickening on the posterior laryngeal wall, tremor in structures (BOT, vallecula), early escape, vallecular stasis in glossoepiglottic folds and pyriform sinus, penetration, tracheal aspiration, cough reflex > CSE (presence/absence) - history of aspiration pneumonia - alert state, interaction attention/ability, postural control, fatiguability - awareness of the swallowing problem & of secretion - ability to manipulate flows - anatomy and oral, pharyngeal and laryngeal physiology - orofacial tones & sensitivity - oral apraxia, swallowing apraxia - gag pharyngeal contraction, cough and hawk - saliva swallowing - oral residue - delayed swallowing reflex, multiple swallowing - reduction in laryngeal elevation > wet voice > FOIS > SWAL-QOL	pre, post (4w)	2
Bajjens, 2012	Netherlands	Feasibility pilot study with control group	20 (N/S)	No	65.5 (46-81)	m=14, f=6	median: 2 (1-3)	mild to severe	SES (VitalStim), 3 different electrode positions applied in random order per subject	Healthy controls with same intervention	VFS: - moment of opening and closing of: glossopalatal junction, velopharyngeal junction, laryngeal vestibule, upper esophageal sphincter - PAS - movement patterns of hyoid bone - extent of movement of hyoid bone - pre-swallow anterior spill - preswallow posterior spill - lingual pumping - swallow hesitancy - piecemeal deglutition - delayed initiation of the pharyngeal reflex - postswallow oral oral residue - postswallow vallecular pooling - postswallow pyriform sinus pooling - PAS	during	1
Bajjens, 2013	Netherlands	quasi-RCT	109 (19)	No	median: 68	m=66, f=24	median: 2(1-4)	mild to severe	IG1: traditional logopedic dysphagia treatment + SES of submental region; motor-level stimulation; IG2: traditional logopedic dysphagia treatment + SES of submental region; sensory-level stimulation	Traditional logopedic dysphagia treatment	> FEES: - Preswallow posterior spill - Piecemeal deglutition - Delayed initiation pharyngeal reflex - Postswallow vallecular pooling - Postswallow pyriform sinus pooling - PAS > VFS: - Preswallow anterior spill - Preswallow posterior spill - Lingual pumping - Swallow hesitancy - Piecemeal deglutition - Delayed initiation pharyngeal reflex - Postswallow oral residue - Postswallow vallecular pooling - Postswallow pyriform sinus pooling - PAS	pre, post (15d)	2

Byeon, 2016	Korea	RCT	33 (N/S)	No	IG: 63.8 (SD ± 8.2) CG: 65.1 (SD ± 9.5)	m=31, f=2	IG: 15 ≤ H&Y 3; 3 > H&Y 4 CG: 11 ≤ H&Y 3; 4 > H&Y 4	N/S	Postural techniques + EMST	EMST	> VFS: - Functional Dysphagia Scale (FDS)	pre, post (4w)	2
Claus, 2021	Germany	RCT	53 (8)	No	IG: 67.3 (54-83; SD ± 9.5) CG: 67.1 (49-82; SD ± 7.7)	IG: m=19, f=5 CG: m=18, f=3	IG: 2.5 (2-4), CG: 2.6 (2-4)	N/S	EMST (calibrated)	EMST (sham)	> FEES (5-point scales): - premature spillage - penetration-aspiration events - residue - total FEES score (0-108) > SWAL-QOL (German) > Swallowing Disturbance Questionnaire (SDQ) (German) > MEG (only 22 patients, sub-group): - frequency bands: theta (4–8 Hz), alpha (8–13 Hz), beta (13–30 Hz), low-gamma, (30–60 Hz), and high-gamma (60–80 Hz) - In all frequency bands: source localization of each subject's swallowing-associated event-related desynchronization (ERD) of cortical rhythms	pre, post (4w, 3m)	3
Feng, 2019	China	CCT	60 (N/S)	No	IG: 65.20 (SD ± 6.84) (54-84) CG: 64.66 (SD ± 5.27) (56-75)	m=38, f=22	N/S	>18 on the SSA (inclusion criterion)	Vocal training + conventional swallowing treatment	Conventional swallowing treatment	> SSA > Evaluation of salivation: - UPDRS II - Drooling Severity and Frequency Scale (DSFS) > Voice evaluation - Maximum phonation time (MPT) - Maximum phonation decibel	pre, post (4w)	2
Heijnen, 2012	Netherlands	quasi-RCT	109 (21)	No	Median 68 (42-81)	m=65, f=23	Median 2 (1-4)	FOIS: median 7 (1-7)	Traditional logopedic dysphagia treatment + NMES (VitalStim) of the supra hyoid musculature; Group 2 (NMES-M); motor level, Group 3	Group 1: traditional logopedic dysphagia treatment	> FOIS > SWAL-QOL (Dutch) > MD Anderson Dysphagia Inventory (MDADI) (Dutch) > Dysphagia Severity Scale (DSS) > FEES > VFS	pre, post, 3m (DSS post each treatment session)	3 (15)
Khedr, 2019	Egypt	RCT	33 (3)	No	IG: 60.7 (SD ± 8.8) CG: 57.4 (SD ± 10.0)	N/S	IG: 3.1 (SD ± 1.1) CG: 3.5 (SD ± 1.0)	SDQ: IG: 17.4 (SD ± 6.1) CG: 16.2 (SD ± 5.8)	Repetitive Transcranial Magnet Stimulation	Sham	> H&Y > UPDRS III > Instrumental Activities of Daily Living (IADL) > Self-assessment scale of swallowing > SDQ > Arabic DHI > VFS (for 9 in IG, 6 in CG, pre, post) - pharyngeal transit time (PTT) - time of first superior-anterior movement of hyoid bone H1 - time when hyoid bone reached its max elevation H2 - time required for max elevation of the hyoid bone H2-H1 - PAS - postswallow residue	pre, post (2w, 1m, 2m, 3m)	5
Kondo, 2017	Japan	RCT	20, thereof 3 with PD (N/S)	No	IG: 80.4 (SD ± 9.5) CG: 80.1 (SD ± 5.9)	m=19, f=1	N/S	N/S	Aural stimulation with capsaicin ointment	Aural stimulation with placebo ointment	> Endoscopic swallowing scoring: - Salivary pooling in vallecula and pyriform sinuses - The response of glottal closure reflex induced by touching epiglottis with endoscope - The location of the bolus at the time of swallow onset assessed by endoscopic whiteout - The extent of pharyngeal clearance after swallowing of blue-dyed water - Total swallowing function > Sensory-Motor-Reflex Clearance (SMRC) scale: - Sensory: Initiation of swallowing reflex as assessed by endoscopic whiteout - Motion: holding bolus in oral cavity and inducing laryngeal elevation according to instructions - Reflex: glottal closure and cough reflexes induced by touching epiglottis or arytenoids with endoscope - Clearance: pharyngeal clearance of bolus after swallowing	pre, post (5, 30, 60 min)	4
Logemann, 2008	United States	RCT	742, thereof 360 with PD (31)	No	range: 50-95	m=498, f=213	N/S	Aspiration of water on VFS (inclusion criterion)	Chin-down posture while consuming thin liquids	No postural adjustment during swallows of nectar and honey-thickened liquids	> VFS: - Aspiration - Preference for different interventions	during	1

Additional file 4: Excluded outcomes

#	Author, Year	Verbatim	Definition	Measurement	Timepoints	Frequency	Reason for exclusion
1	Ayres, 2017	Prior state of secretion in nasopharyngeal structures, oropharynx, laryngopharynx	N/S	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
2	Ayres, 2017	Thickening on the posterior laryngeal wall	Presence/absence of thickening on the posterior laryngeal wall	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
3	Ayres, 2017	Tremor in structures (BOT, vallecula)	Presence/absence of tremor in structures (BOT, valleculae)	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
4	Ayres, 2017	Early escape	Characterized by the presence of food in the hypopharynx or larynx before the swallowing reflex was triggered	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
5	Ayres, 2017	Vallecular stasis in glossoepiglottic folds and pyriform sinus	Characterized by accumulation of food after the third swallowing on the mentioned structures	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
6	Ayres, 2017	Penetration	Characterized by the presence of food in the laryngeal vestibule	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
7	Ayres, 2017	Tracheal aspiration	Characterized by food intake in the region located below the vocal folds, in the subglottic region and in the trachea, at any time of swallowing	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
8	Ayres, 2017	Cough reflex	Presence/absence	FEES	pre, post (4w)	2	Observations that were made, but not measured and not reported
9	Ayres, 2017	Ability to manipulate flows	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
10	Ayres, 2017	Postural control	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
11	Ayres, 2017	Fatiguability	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
12	Ayres, 2017	Anatomy and oral, pharyngeal and laryngeal physiology	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
13	Ayres, 2017	Orofacial tones	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
14	Ayres, 2017	Oral apraxia	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
15	Ayres, 2017	Orofacial sensitivity	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
16	Ayres, 2017	Gag pharyngeal contraction	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported

17	Ayres, 2017	Saliva swallowing	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
18	Ayres, 2017	Cough and hawk	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
19	Ayres, 2017	Swallowing apraxia	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
20	Ayres, 2017	Oral residue	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
21	Ayres, 2017	Delayed swallowing reflex	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
22	Ayres, 2017	Reduction in laryngeal elevation	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
23	Ayres, 2017	Wet voice	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
24	Ayres, 2017	Multiple swallowing	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
25	Ayres, 2017	History of aspiration pneumonia	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
26	Ayres, 2017	Intake of food	Level of oral food intake	FOIS	pre, post (4w)	2	Observations that were made, but not measured and not reported
27	Ayres, 2017	Interaction attention/ability	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
28	Ayres, 2017	Alert state	presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
29	Ayres, 2017	Awareness of the swallowing problem	Presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
30	Ayres, 2017	Awareness of secretion	presence/absence	CSE	pre, post (4w)	2	Observations that were made, but not measured and not reported
31	Feng, 2019	Consciousness	N/S	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
32	Feng, 2019	Head and trunk control	N/S	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
33	Feng, 2019	Lip closure	N/S	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
34	Feng, 2019	Voice strength	N/S	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
35	Feng, 2019	Gag reflex	N/S	SSA	pre, post (4w)	2	Observations that were made for overall SSA score

36	Feng, 2019	Laryngeal movement	Presence/absence by observation of the patient drinking (scale from 18-46)	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
37	Feng, 2019	Repetitive swallowing	Presence/absence by observation of the patient drinking (scale from 18-46)	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
38	Feng, 2019	Laryngeal function after swallowing	Presence/absence by observation of the patient drinking (scale from 18-46)	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
39	Feng, 2019	Time required to swallow	Presence/absence by observation of the patient drinking (scale from 18-46)	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
40	Feng, 2019	Breathing	clinical examination (scale from 18-46)	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
41	Feng, 2019	Wheezing during swallowing	presence/absence by observation of the patient drinking (scale from 18-46)	SSA	pre, post (4w)	2	Observations that were made for overall SSA score
42	Heijnen, 2012	N/S	N/S	FEES	N/S	N/S	No specification of outcomes being measured
43	Heijnen, 2012	N/S	N/S	VFS	N/S	N/S	No specification of outcomes being measured
44	Khedr, 2019	Diagnosis of dysphagia	- N/S (a score on the SDQ of ≥ 11 indicates dysphagia.)	SDQ	pre	1	Is reported as an outcome but was only conducted for assessing dysphagia pre treatment for inclusion
45	Silva-Arone, 2021	N/S	N/S	VFS: Eisenhuber scale	pre, post (3m, 6m)	3	No specification, outcome was only reported in unpublished Master thesis, referenced by Battel et al. (2020)
46	Wei, 2017	Mis-inhalation	N/S	N/S	post (6m)	1	No definition of the outcome, unclear to what this relates and what was measured

CSE: Clinical Swallow Evaluation; FEES: Fiberoptic Evaluation of Swallowing; N/S: not specified; SDQ: Swallowing Disturbance Questionnaire; SSA: Standardized Swallow Assessment; VFS: Videofluoroscopy of Swallowing; w: weeks

Additional file 5: Definitions of outcomes

Outcome	Definition
Death	N/S
Oropharyngeal dysphagia severity	N/S
Drooling	Severity and frequency of drooling
Salivary pooling	Salivary pooling in vallecula and pyriform sinuses
Orolingual bolus control	3x N/S; Preswallow loss of bolus from lips/into pharynx; Premature spillage: materials spilled over the base of the tongue into the hypopharynx (including the valleculae, the lateral channels, and the pyriform sinus) too early during the oral swallowing stage, meaning before the pharyngeal swallow was initiated.
Oral bolus transport	Swallow hesitancy; delayed onset oral transport
Swallowing related lingual movement pattern	Preswallow involuntary repetitive tongue movements
Timing of oropharyngeal swallow components	GPJo (glossopalatal junction opening): N/S
	GPJc (glossopalatal junction closure): N/S
	VPJo (velopharyngeal junction opening): Moment of separation of soft palate and posterior pharyngeal wall with re-entry of air in retrolingual space from nasopharynx (in seconds)
	VPJc (velopharyngeal junction closure): Moment of separation of soft palate and posterior pharyngeal wall with re-entry of air in retrolingual space from nasopharynx (in seconds)
	VPJd (velopharyngeal junction duration): ΔT between VPFc and VPJo (in seconds)
	Lvo (laryngeal vestibule opening): Moment of separation of arytenoid cartilages and underside of epiglottis with re-entry of air in laryngeal vestibule (in seconds)

LVc (laryngeal vestibule closure): Moment when laryngeal elevation results in making contact between arytenoid cartilages and underside of epiglottis (in seconds)

LVd (laryngeal vestibule duration): ΔT between LVc and LVo (in seconds)

UESo (upper esophageal sphincter opening): N/S

UESc (upper esophageal sphincter closure): Moment of closure of esophagus after bolus transport (in seconds)

GPJo (glossopalatal junction opening) – LVc (laryngeal vestibule closure): ΔT between GPJo and LVc (in seconds)

Duration horizontal hyoid motion: Duration between initiation of swallow and moment of maximum horizontal (anterior) motion (in seconds)

Duration vertical hyoid motion: Duration between initiation of swallow and moment of maximum vertical motion (in seconds)

Pharyngeal transit time (PTT): From the point where the bolus head moved from the hold position and passed the posterior nasal spine until it fully entered the esophagus after the closure of the upper esophageal sphincter (in seconds)

Time required for max elevation of the hyoid bone: H2-H1: The time of the first superior-anterior movement of the hyoid bone was assigned as H1, and the time when the hyoid bone reached its maximum elevation was assigned as H2.

Bolus flow time: Measurement of the time when the bolus is seen in the hypopharynx until it triggers the swallowing reflex (0 = 0-1 s, 1 = 2-4 s, 2 = 5-7 s, 3 = 8 + s)

Oral transit time (OTT): N/S

Pharyngeal transit time (PTT): N/S

Pharyngeal response time (PRT): N/S

Duration of hyoid movement: measurement tags at 1) the initiation of hyoid movement which resulted in the swallow and 2) the point when the hyoid returned to rest following the completion of the swallow. These tags were then used to calculate the duration of hyoid (in seconds) movement.

Laryngeal elevation	N/S
Laryngeal sensation	The response of glottal closure reflex induced by touching epiglottis with endoscope; Glottal closure and cough reflexes induced by touching epiglottis or arytenoids with endoscope
Piecemeal deglutition	Sequential swallowing of same bolus
Swallowing related hyoid bone movement	<p>Movement patterns of hyoid bone: Anterior/superior corner of hyoid bone (x axis), anterior/inferior corner of third and fifth cervical vertebral bodies (y axis)</p> <p>Extent of movement of hyoid bone: Extent of movement in x-y coordinate system over time</p> <p>Vertical hyoid motion: Maximum vertical motion during swallowing act (in mm)</p> <p>Horizontal displacement of the hyoid bone: The distance (in cm) from the resting position to the maximal excursion position during swallowing; the most supero-anterior point of the hyoid indicates maximum displacement after swallowing</p> <p>Vertical displacement of the hyoid bone: The distance (in cm) from the resting position to the maximal excursion position during swallowing; the most supero-anterior point of the hyoid indicates maximum displacement after swallowing</p> <p>Hyoid displacement - Onset of bolus transit: Bolus head arrival at posterior edge of ramus of mandible</p> <p>Hyoid displacement - UES-opening: Forward displacement of cricoid cartilage from posterior pharyngeal wall</p> <p>Hyoid displacement - UES-widset: Widest part of bolus head passing through UES</p> <p>Hyoid displacement - UES-closure: Last point when UES is open</p> <p>Hyoid displacement - Laryngeal closure: Forward displacement of arytenoid cartilage to epiglottic petiole</p> <p>Hyoid displacement - Max laryngeal closure: Maximum contact of arytenoid cartilages with epiglottic petiole</p> <p>Hyoid displacement - Laryngeal opening: First separation of arytenoid cartilages from epiglottic petiole</p>

Initiation of pharyngeal swallow	Delayed initiation pharyngeal triggering; the location of the bolus at the time of swallow onset; Initiation of swallowing reflex; Bolus location when the swallowing reflex is triggered; Initiation time of the swallowing reflex
Postswallow oral residue	1x N/S, Pooling in oral cavity after the swallow
Postswallow pharyngeal residue	1x N/S; Material was insufficiently cleared from the hypopharynx during swallowing and remained after swallowing; The extent of pharyngeal clearance after swallowing; Residue location of the food
Postswallow pharyngeal pooling	Postswallow pooling in valleculae; Pooling in valleculae after the swallow; Pooling in pyriform sinuses after the swallow
Piecemeal deglutition	Sequential swallowing of same bolus
Penetration/Aspiration	2x N/S; Definitions of penetration and aspiration according to Rosenbek et al. 1996, Penetration and/or aspiration; Penetration: material entered the laryngeal vestibule (defined by Langmore's epiglottis level 3) but remained at or above the level of the vocal cords; Aspiration: material entered the airway below the vocal cords; Penetration/aspiration of food/liquid before/after swallowing
Cortical reorganization	N/S
Motor evoked potential (MEP)	Amplitude: N/S Latency: the time in milliseconds from the point at which a TMS pulse was delivered to the onset of a MEP
Overall motor symptoms	N/S
Tremor	N/S
Rigidity	N/S
Bradykinesia	N/S
Axial symptoms	N/S
Freezing of gait	Number of Freezing of gait spells, time to complete test
Phonation	N/S
Loudness	N/S
Level of oral intake	N/S

Aspiration pneumonia	Chest radiography: evidence of pneumonia Clinical evaluation: 3 or more of the following: sustained fever (temperature > 100 °F [38 °C]), rales or rhonchi on chest auscultation, sputum Gram stain showing substantial leukocytes, or sputum culture showing a respiratory pathogen
Activities of daily living	N/S
Pleasure of oral intake	Patient's degree of enjoyment from food
Swallowing related quality of life	N/S
Self-perception of swallowing	4x N/S; Changes in patient subjective dysphagia symptoms as well as swallowing-related quality of life
Self-perception of walking	Patient's perception of walking difficulty
Self-perception of activities of daily living	N/S
Patient's satisfaction with intervention	1x N/S; Preference for different interventions
Patient's adherence to intervention	N/S
Hospitalization	N/S
Adverse events	Any clinically significant event possibly related to the assigned intervention (for example, dehydration), no report of events expected as part of the participant's disease progression or aging process (for example, worsening of Parkinson disease symptoms), all adverse events were rated as mild, moderate, severe, or life-threatening

N/S: not specified; T: time; TMS: Transcranial Magnetic Stimulation; UES: upper esophageal sphincter

Additional file 6: Outcome measurement instruments

Outcome	Measurement
Death	N/S
Oropharyngeal dysphagia severity	VFS: DOSS (O'Neil et al., 1999); FDS (Han et al., 1999); VDS-total; -oral; -pharyngeal (Kim et al., 2012) FEES: score 0-108; sum of 5 scores; sum of 4 scores Dysphagia scale (no reference, from Wei et al. 2017); SSA (Perry et al., 2001); CSE
Drooling	UPDRS II: 5-point scale DSFS: 5- and 4-point scale (Thomas-Stonell & Greenberg, 1988)
Salivary pooling	FEES: 4-point scale
Orolingual bolus control	VFS: 5-point scale FEES: 3-point-scale, 5-point scale
Oral bolus transport	VFS: 3-point scale
Swallowing related lingual movement	VFS: 5-point scale
Timing of oropharyngeal swallow components	VFS FEES: 4-point scale
Laryngeal elevation	FEES: 3-point scale
Laryngeal sensation	FEES: touching epiglottis or arytenoids with endoscope, 4-point scale
Swallowing related hyoid bone movement	VFS: in milli- or centimeters
Initiation of pharyngeal swallow	VFS: 3-point scale FEES: endoscopic whiteout, 4-point scale; 3-point scale EMG (submental muscles) in milliseconds
Postswallow oral residue	VFS: 5-point scale
Postswallow pharyngeal residue	VFS: 3-point scale FEES: 4-point scale; 5-point scale
Postswallow pharyngeal pooling	VFS: 3-point scale FEES: 3-point scale
Piecemeal deglutition	VFS: 5-point scale FEES: 5-point scale
Penetration/Aspiration	VFS: PAS, 8-point scale (Rosenbek et al., 1996) FEES: PAS, 8-point scale (Rosenbek et al., 1996); penetration/aspiration before/after swallowing, 4-point scale
Cortical reorganization	Magnetoencephalography: data filtered within theta (4–8 Hz), alpha (8–13 Hz), beta (13–30 Hz), low-gamma, (30–60 Hz), high-gamma (60–80 Hz) frequency bands; in all frequency bands, performance of source localization of each subject's swallowing-associated event-related desynchronization (ERD) of cortical rhythms
Motor evoked potential	Electromyography
Overall motor symptoms	H&Y; UPDRS III

Tremor	UPDRS III
Rigidity	UPDRS III
Bradykinesia	UPDRS III
Axial symptoms	UPDRS III
Freezing of gait	Stand-walk-test (no reference, from Xie et al., 2018)
Phonation	Maximum phonation time on /aa/ in seconds
Loudness	Maximum phonation decibel (dB) on /aa/
Level of oral intake	FOIS (Crary et al., 2005)
Aspiration pneumonia	Chest radiography Clinical evaluation: ≥ 3 of the following: sustained fever (temperature > 100 °F [38 °C]), rales or rhonchi on chest auscultation, sputum Gram stain showing substantial leukocytes, or sputum culture showing a respiratory pathogen
Activities of daily living	IADL (Lawton et al., 1969)
Pleasure of oral intake	POE (Manor et al., 2013)
Swallowing related quality of life	SWAL-QOL (McHorney et al., 2002), MDADI (Chen et al., 2001)
Self-perception of swallowing	SDQ (Manor et al., 2007), DSS (Tohara et al., 2003), A-DHI (Farahat et al., 2014)
Self-perception of walking	FOG questionnaire (Giladi et al., 2009)
Self-perception of activities of daily living	Activities of Daily Living Scale (Brown et al., 1989)
Patient's satisfaction with intervention	Interview: rated as easy/pleasant, average, or difficult/unpleasant SWAL-CARE (McHorney et al., 2002)
Patient's adherence to intervention	Assessed across meals, classified monthly as 0% - 25%, 26% - 50%, 51% - 75%, or 76% - 100%
Hospitalization	N/S
Adverse events	Clinical evaluation

A-DHI = Arabic Dysphagia Handicap Index, CSE = Clinical Swallow Evaluation, DOSS = Dysphagia Outcome and Severity Scale, DSFS = Drooling Severity and Frequency Scale, DSS = Dysphagia Severity Scale, EMG = Electromyography, FDS = Functional Dysphagia Scale, FEES = Fiberoptic Endoscopic Evaluation of Swallowing, FOG = Freezing of Gait, FOIS = Functional Oral Intake Scale, H&Y = Hoehn & Yahr, IADL = Instrumental Activities of Daily Living, MDADI = MD Anderson Dysphagia Inventory, N/S = not specified, PAS = Penetration-Aspiration-Scale, POE = Pleasure of Eating, SDQ = Swallowing Disturbance Questionnaire, SSA = Standardized Swallowing Assessment, SWAL-CARE = Swallowing Quality of Care Questionnaire, SWAL-QOL = Swallowing Quality of Life Questionnaire, UPDRS = Unified Parkinson's Disease Rating Scale, VDS = Videofluoroscopic Dysphagia Scale, VFS = Videofluoroscopic Evaluation of Swallowing

Additional file 7: Timepoints and frequency of measurement

Outcome	Timepoints of measurement	Frequency of measurement
Death	continuously during 3m	continuously
Oropharyngeal dysphagia severity	pre, post (5min, 30min, 60min, 2w, 1m, 3m, 6m)	1 to 3
Drooling	pre, post (4w)	2
Salivary pooling	pre, post (5min, 30min, 60min)	4
Orolingual bolus control	during, pre, post (5min, 30min, 60min, 15d, 1m, 3m)	1 to 4
Oral bolus transport	during, pre, post (15d)	1 to 2
Swallowing related lingual movement	pre, post (15d)	2
Timing of oropharyngeal swallow components	during, pre, post (0min, 2w, 4w)	1 to 2
Laryngeal elevation	pre, post (5min, 30min, 60min)	4
Laryngeal sensation	pre, post (5min, 30min, 60min)	4
Swallowing related hyoid bone movement	during, pre, post (4w)	1 to 2
Initiation of pharyngeal swallow	during, pre, post (0d, 5min, 30min, 60min, 15d, 2w)	1 to 4
Postswallow oral residue	during, pre, post (15d)	1 to 2
Postswallow pharyngeal residue	pre, post (5min, 30min, 60min, 2w, 1m, 3m)	2 to 4
Postswallow pharyngeal pooling	during, pre, post (15d)	1 to 2
Piecemeal deglutition	during, pre, post (15d)	1 to 2
Penetration/Aspiration	during, pre, post (0min, 15d, 2w, 1m, 3m) V1: during; V2 (at least 6m later): during	1 to 2
Cortical reorganization	pre, post (1m)	2
Motor evoked potential (MEP)	pre, post (0min, 30min)	3
Overall motor symptoms	pre, post (2w, 1m, 2m, 3m) V1: during; V2 (at least 6m later): during	2 to 5
Tremor	V1: during; V2 (at least 6m later): during	2
Rigidity	V1: during; V2 (at least 6m later): during	2
Bradykinesia	V1: during; V2 (at least 6m later): during	2
Axial symptoms	V1: during; V2 (at least 6m later): during	2
Freezing of gait	V1: during; V2 (at least 6m later): during	2
Phonation	pre, post (4w)	2
Loudness	pre, post (4w)	2
Level of oral intake	pre, post (3m, 6m)	3
Aspiration pneumonia	continuously during 3m	continuously
Activities of daily living	pre, post (2w, 1m, 2m, 3m)	5
Pleasure of oral intake	pre, post (2w, 4w)	3
Swallowing related quality of life	pre, post (1m, 3m, 6m)	2 to 3
Self-perception of swallowing	pre, post (2w, 1m, 2m, 3m, 6m) 2 x pre, after each session (13-15), 2 x post V1: post (30 min); V2 (at least 6m later): post (30min)"	2 to 15
Self-perception of walking	V1: during; V2 (at least 6m later): during	2
Self-perception of activities of daily living	pre, post (2w, 1m, 2m, 3m)	5
Patient's satisfaction with intervention	during, post (2w)	1
Patient's adherence to intervention	weekly	36
Hospitalization	continuously during 3m	continuously
Adverse events	continuously during 3m	continuously

min: minutes; d: days; w: weeks; m: months; V1: visit 1; V2: visit 2

Additional file 8: Excluded reports with reasons for exclusion

#	Study	Reason for exclusion
1	Antonello, N., & Grecchi, B. (2019). EFFECTIVENESS OF AN EXPIRATORY FLOW ACCELERATION DEVICE IN DYSPHAGIC PATIENTS WITH PARKINSON DISEASE. <i>Chest</i> , 156(4), A1784–A1785. https://doi.org/10.1016/j.chest.2019.08.1549	Congress abstract of Riboldazzi et al. 2020
2	Baijens, L., Speyer, R., & Pilz, W. (2011). The effect of surface electrical stimulation on swallowing in Parkinson's disease. <i>Dysphagia</i> , 26(4), 462. https://doi.org/10.1007/s00455-011-9345-1	Congress abstract on Baijens et al. 2012
3	Baijens, L. W. J., Speyer, R., Passos, V. L., Pilz, W., Van Der Kruis, J., Haarmans, S., & Desjardins-Rombouts, C. (2014). Surface electrical stimulation in dysphagic parkinson patients: A Randomized clinical trial. <i>Dysphagia</i> , 29(3), 404. https://doi.org/10.1007/s00455-014-9536-7	Comment on Baijens et al. 2013
4	Bird, M., Woodward, M., Gibson, E., Phyland, D., & Fonda, D. (1996). The effect of levodopa on swallowing in Parkinson's disease: Are there benefits in administration before meals? <i>AUSTRALIAN JOURNAL ON AGEING</i> , 15(1), 27–29. https://doi.org/10.1111/j.1741-6612.1996.tb00196.x	Wrong patient population (Parkinson's disease without oropharyngeal dysphagia)
5	Bushmann, M., Dobmeyer, S. M., Leeker, L., & Perlmutter, J. S. (1989). Swallowing abnormalities and their response to treatment in Parkinson's disease. <i>Neurology</i> , 39(10), 1309–1314. https://doi.org/10.1212/wnl.39.10.1309	Wrong study design (no control group)
6	Claus, I., Muhle, P., Suttrup, J., Schroeder, J. B., Suntrup-Krueger, S., Dziewas, R., & Warnecke, T. (2020). Expiratory muscle strength training (EMST) for treatment of pharyngeal dysphagia in Parkinson's disease: A randomized controlled trial. <i>Dysphagia</i> , 35(1), 143. https://doi.org/10.1007/s00455-019-10078-x	Congress abstract on Claus et al. 2021
7	De Graaf, L. (2007). Loss of saliva due to dysphagia: Patients with Parkinson's disease benefit from explanation and training. <i>Pharmaceutisch Weekblad</i> , 142(18), 29–31.	Wrong study design (no clinical intervention)
8	FENG Qing-ling, CHENG Yuan-yuan, LIU Pei-pei, ZHOU Xiao-na, WANG Yue, CHEN Rong-jie, YU Yang, & WU Jia-ling. (2019). Effects of vocalization training on drooling severity in Parkinson's disease. <i>Chinese Journal of Contemporary Neurology & Neurosurgery</i> , 19(11), 891–896.	Congress abstract on Feng et al. 2019

9	Jost, W. H., Michel, O., Oehlwein, C., Slawek, J., Bogucki, A., Ochudlo, S., Banach, M., Pagan, F., Flatau-Baqué, B., Csikós, J., & Blitzer, A. (2018). Efficacy of incobotulinumtoxinA in subjects with sialorrhea, assessed using the modified radboud oral motor inventory for Parkinson's disease (mROMP). <i>Toxicon</i> , 156, S53–S54. https://doi.org/10.1016/j.toxicon.2018.11.127	Congress abstract on Jost et al. 2019
10	Jost, W. H., Friedman, A., Michel, O., Oehlwein, C., Slawek, J., Bogucki, A., Ochudlo, S., Banach, M., Pagan, F., Flatau-Baqué, B., Dorsch, U., Csikós, J., & Blitzer, A. (2020). Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks. <i>Parkinsonism & Related Disorders</i> , 70, 23–30. https://doi.org/10.1016/j.parkreldis.2019.11.024	No swallowing related outcomes included
11	Kitashima, A., Umamoto, G., Tsuboi, Y., Higuchi, M., Baba, Y., & Kikuta, T. (2013). Effects of subthalamic nucleus deep brain stimulation on the swallowing function of patients with Parkinson's disease. <i>Parkinsonism & Related Disorders</i> , 19(4), 480–482. https://doi.org/10.1016/j.parkreldis.2012.10.023	Wrong study design (no control group)
12	Kondo, E., Takeda, N., & Jinnouchi, O. (2017). Aural stimulation with capsaicin ointment improved the swallowing function in patients with dysphagia: A randomized, placebo-controlled, double-blind, comparative study. <i>Dysphagia</i> , 32(6), 817. https://doi.org/10.1007/s00455-017-9805-3	Congress abstract on Kondo et al. 2017
13	Manor, Y., Freud, D., Mootanah, R., Gurevich, T., Giladi, N., & Jacob, C. T. (2010). Video assisted swallowing therapy improved quality of life measures more than traditional swallowing therapy in patients with Parkinson's disease. <i>Movement Disorders</i> , 25, S427. https://doi.org/10.1002/mds.23162	Congress abstract on Manor et al. 2013
14	Marks, L., Turner, K., O'Sullivan, J., Deighton, B., & Lees, A. (2001). Drooling in Parkinson's disease: A novel speech and language therapy intervention. <i>International Journal of Language & Communication Disorders</i> , 36 Suppl, 282–287. https://doi.org/10.3109/13682820109177898	Wrong patient population (Parkinson's disease without oropharyngeal dysphagia)
15	Merello, M., Starkstein, S., Nouzeilles, M. I., Kuzis, G., & Leiguarda, R. (2001). Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. <i>Journal of Neurology, Neurosurgery, and Psychiatry</i> , 71(5), 611–614. https://doi.org/10.1136/jnnp.71.5.611	No swallowing related outcomes included
16	Necati, E., Demir, N., Serel Arslan, S., Eker, A., Kaymakamzade, B., & Karaduman, A. A. (2020). Effect of kinesio taping on swallowing function in parkinson patients: A surface electromyographic swallowing study. <i>Turkish Journal of Physiotherapy and Rehabilitation</i> , 31(2), 202–209. Embase. https://doi.org/10.21653/tjpr.540557	Wrong patient population (Parkinson's disease without oropharyngeal dysphagia)

17	Nozaki, S., Matsui, T., Yoshikawa, H., Kaneto, T., Domen, K., & Daimon, T. (2013). Metronome therapy to treat dysphagia in patients with parkinson's disease. <i>Dysphagia</i> , 28(2), 298. https://doi.org/10.1007/s00455-013-9455-z	Full text not available (provided email address is inactive, no further contact address could be identified, full text could not be retrieved)
18	Nozaki, S., Sugishita, S., Imai, T., Oguro, D., Inokawa, M., Matsui, T., Umaki, Y., Kaneto, T., Domen, K., & Yoshikawa, H. (2011). Training for dysphagia with metronome improves swallowing function in parkinson disease. <i>Dysphagia</i> , 26(4), 443. https://doi.org/10.1007/s00455-011-9345-1	Full text not available (provided email address is inactive, no further contact address could be identified, full text could not be retrieved)
19	Oh, E., Sookyong, B., Soyoung, A., & Sungjoo, J. (2019). Developing silver food which is easy to swallow in patients with Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 9(1), 180–181. Embase. https://doi.org/10.3233/JPD-199900	Congress abstract on Oh et al. 2021
20	Oh, E., Jee, S., Kim, B. K., Lee, J. S., Cho, K., & Ahn, S. (2021). A new swallowing supplement for dysphagia in patients with Parkinson's disease. <i>Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</i> , 42(5), 1949–1958. https://doi.org/10.1007/s10072-020-04730-w	Wrong study design (no control group)
21	Ondo, W. G., Hunter, C., & Moore, W. (2004). A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. <i>Neurology</i> , 62(1), 37–40. https://doi.org/10.1212/01.wnl.0000101713.81253.4c	No swallowing related outcomes included
22	Pflug, C., Nienstedt, J. C., Gulberti, A., Müller, F., Vettorazzi, E., Koseki, J.-C., Niessen, A., Flügel, T., Hidding, U., Buhmann, C., Weiss, D., Gerloff, C., Hamel, W., Moll, C. K. E., & Pötter-Nerger, M. (2020). Impact of simultaneous subthalamic and nigral stimulation on dysphagia in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 7(5), 628–638. https://doi.org/10.1002/acn3.51027	Wrong patient population (Parkinson's disease without oropharyngeal dysphagia)
23	Restivo, D. A., Palmeri, A., & Marchese-Ragona, R. (2002). Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. <i>The New England Journal of Medicine</i> , 346(15), 1174–1175. https://doi.org/10.1056/NEJM200204113461517	Wrong study design (no clinical intervention for oropharyngeal dysphagia)
24	Riboldazzi, G., Spinazza, G., Beccarelli, L., Prato, P., Grecchi, B., D'Abrosca, F., & Nicolini, A. (2020). Effectiveness of expiratory flow acceleration in patients with Parkinson's disease and swallowing deficiency: A preliminary study. <i>Clinical Neurology and Neurosurgery</i> , 199, 106249. https://doi.org/10.1016/j.clineuro.2020.106249	No swallowing related outcomes included

25	Saleem, A., Sapienza, C., Rosenbek, J., Musson, N., & Okun, M. (2005). The effects of expiratory muscle strength training program on pharyngeal swallowing in patients with idiopathic Parkinson's disease. <i>MOVEMENT DISORDERS</i> , 20, S73–S74.	Congress abstract, full text not available; most likely on Troche et al. 2010
26	Saleem, A., Sapienza, C., Rosenbek, J., Musson, N., & Okun, M. (2005). The effects of expiratory muscle strength training on pharyngeal swallowing in patients with idiopathic Parkinson's disease. <i>NEUROLOGY</i> , 64(6), A397–A397.	Congress abstract, full text not available; most likely on Troche et al. 2010
27	Sapienza, C. M., Troche, M., Silverman, E. P., Rosenbek, J., & Musson, N. (2012). Strength training outcomes for airway protection in PD. <i>Movement Disorders</i> , 27, S139. https://doi.org/10.1002/mds.25051	Congress abstract, full text not available; most likely on Troche et al. 2010
28	Sapienza, C., Troche, M., Silverman, E., Rosenbek, J., Musson, N., & Okun, M. (2011). Strength training outcomes for airway protection in PD. <i>Neurodegenerative Diseases</i> , 8. https://doi.org/10.1159/000327701	Congress abstract, full text not available; most likely on Troche et al. 2010
29	Sordoni, E., Andrenelli, E., Di Biagio, L., Millevolte, M., Ceravolo, M. G., & Capecci, M. (2014). Comparative efficacy and safety of botulinum toxin type A and B in treating Parkinson's disease-related sialorrhea: A pre-test post-test study. <i>Annals of Physical and Rehabilitation Medicine</i> , 57, e363–e364. https://doi.org/10.1016/j.rehab.2014.03.1215	Congress abstract, full text not available, contacted first and second author, awaiting response
30	Sundstedt, S., Nordh, E., Linder, J., Hedström, J., Finizia, C., & Olofsson, K. (2017). Swallowing Quality of Life After Zona Incerta Deep Brain Stimulation. <i>The Annals of Otolaryngology, Rhinology, and Laryngology</i> , 126(2), 110–116. https://doi.org/10.1177/0003489416675874	Wrong patient population (Parkinson's disease without oropharyngeal dysphagia)
31	Tawadros, P., Cordato, D., Cathers, I., & Burne, J. (2012). An Electromyographic Study of Parkinsonian Swallowing and Its Response to Levodopa. <i>MOVEMENT DISORDERS</i> , 27(14), 1811–1815. https://doi.org/10.1002/mds.25262	Wrong study design (no control group)
32	Troche, M., Okun, M., Rosenbek, J., Musson, N., & Sapienza, C. (2009). Swallow outcomes following intervention with expiratory muscle strength training (EMST) in Parkinson's disease: Results of a randomized clinical trial. <i>Dysphagia</i> , 24(4), 455–456. https://doi.org/10.1007/s00455-009-9233-0	Congress abstract on Troche et al. 2010
33	Troche, M., Rosenbek, J., Okun, M., & Sapienza, C. (2011). Swallowing and breathing related outcomes following detraining in EMST. <i>Dysphagia</i> , 26(4), 443–444. Embase. https://doi.org/10.1007/s00455-011-9345-1	Congress abstract on Troche et al. 2010
34	Wu, M.-X., Wang, L.-G., Li, H.-P., & Zeng, X. (2021). [Acupuncture adjuvant treatment for dysphagia in patients with Parkinson's disease: A randomized controlled trial]. <i>Zhongguo zhen jiu = Chinese acupuncture & moxibustion</i> , 41(5), 485–488. https://doi.org/10.13703/j.0255-2930.20200724-0002	Full text not available (no contact address could be identified; full text could not be retrieved)

35	Xie, T., Bloom, L., Padmanaban, M., Bertacchi, B., Kang, W., Dachman, A., MacCracken, E., Zadikoff, C., Markopoulou, K., Warnke, P., & Kang, U. (2018). Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. <i>Movement Disorders</i> , 33, S263.	Congress abstract on Xie et al. 2018
36	Xie, T., Bloom, L., Padmanaban, M., Takahashi, K., Kang, W., Dachman, A., MacCracken, E., & Warnke, P. (2021). Impact of oral textures on aspiration and changes in swallow dynamics in patients with PD with DBS. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> , 92(4), 447–449. https://doi.org/10.1136/jnnp-2020-324579	Same participants and study as in Xie et al. 2018, different outcomes, but not a full report of the study, "letter to the editor"
37	陈艳红, 孙涛, & 陈敏. (2017). 门德尔松手法联合康复训练治疗帕金森病病人吞咽障碍的疗效观察. <i>Chinese Nursing Research</i> , 31(7), 864–866. https://doi.org/10.3969/j.issn.1009-6493.2017.07.032	Full text not available (no contact address could be identified; full text could not be retrieved)
